#1 Clinical Trials Search in Europe

Pomalidomide

Pomalidomide is an immunomodulatory drug that has shown significant potential in the treatment of multiple myeloma and other conditions. This article explores the use of pomalidomide in various clinical trials, highlighting its efficacy, safety profile, and potential applications across different patient populations and disease states.

Table of Contents

What is Pomalidomide?

Pomalidomide is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs called immunomodulators, which means it works by modifying the body’s immune response[1]. Pomalidomide is derived from thalidomide, but it has been designed to be more potent and potentially have fewer side effects[1].

This drug is also known by several other names, including:

What Conditions Does Pomalidomide Treat?

Pomalidomide is primarily used to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow[1]. Specifically, it is used in patients who have:

  • Relapsed multiple myeloma (cancer that has returned after treatment)
  • Refractory multiple myeloma (cancer that has not responded to other treatments)
  • Received at least two prior treatments, including both lenalidomide and bortezomib (other cancer medications)[5]

In addition to multiple myeloma, research is being conducted to evaluate pomalidomide’s effectiveness in treating other conditions, such as:

  • Advanced soft tissue sarcomas (a type of cancer that begins in the tissues that connect, support, and surround other body structures)[4]
  • Recurrent or progressive primary brain tumors in children and young adults[6]

How Does Pomalidomide Work?

Pomalidomide works in several ways to fight cancer:

  1. It helps the immune system attack cancer cells
  2. It interferes with the growth of cancer cells
  3. It reduces inflammation in the body
  4. It may help prevent the formation of new blood vessels that feed tumors (a process called angiogenesis)[1]

These combined effects make pomalidomide a powerful tool in fighting multiple myeloma and potentially other types of cancer.

How is Pomalidomide Administered?

Pomalidomide is typically taken orally (by mouth) as a capsule or tablet. The usual dosing schedule is:

  • 4 mg once daily
  • Taken on days 1-21 of repeated 28-day cycles
  • Often combined with dexamethasone (a steroid medication)[5]

It’s important to note that the exact dosage and schedule may vary depending on the individual patient and the specific condition being treated. Always follow your doctor’s instructions carefully.

How Effective is Pomalidomide?

Clinical trials have shown promising results for pomalidomide in treating multiple myeloma, particularly in patients who have not responded well to other treatments. Some key findings include:

  • Improved progression-free survival (the time during and after treatment when the cancer does not get worse)
  • Increased overall survival rates
  • Higher response rates (the percentage of patients whose cancer shrinks or disappears after treatment)[1][3]

For example, one study reported a 63% objective response rate (meaning the cancer shrank or disappeared) in patients taking pomalidomide plus dexamethasone, including patients with multiple myeloma that was resistant to other treatments[3].

What are the Side Effects of Pomalidomide?

Like all medications, pomalidomide can cause side effects. Some of the most common side effects include:

  • Fatigue (feeling very tired)
  • Nausea (feeling sick to your stomach)
  • Constipation
  • Diarrhea
  • Shortness of breath
  • Low blood cell counts, which can increase the risk of infections and bleeding[4]

More serious side effects can occur, including blood clots and birth defects. For this reason, pomalidomide is subject to special safety measures, including a pregnancy prevention program for patients who can become pregnant[2].

Ongoing Research and Future Directions

Researchers continue to study pomalidomide to understand its full potential. Current areas of investigation include:

  • Combining pomalidomide with other cancer drugs to improve effectiveness[7]
  • Using pomalidomide to treat other types of cancer, such as brain tumors and soft tissue sarcomas[6][4]
  • Exploring different dosing schedules to maximize benefits and minimize side effects[3]
  • Studying pomalidomide’s long-term effects and safety profile[2]

These ongoing studies may lead to new uses for pomalidomide and improved treatment strategies for patients with multiple myeloma and other cancers.

Aspect Details
Primary Use Treatment of relapsed or refractory multiple myeloma
Other Potential Uses Soft tissue sarcomas, Waldenstrom macroglobulinemia, hereditary hemorrhagic telangiectasia
Administration Oral, typically 2-4 mg daily for 21 or 28 days per cycle
Common Side Effects Bone marrow suppression, skin reactions, gastrointestinal issues, infections
Efficacy in Multiple Myeloma Objective response rates over 60% in some studies
Ongoing Research Maintenance therapy, combination treatments, use in other conditions
Safety Profile Generally well-tolerated, lower risk of peripheral neuropathy compared to thalidomide

FAQ

  • What is pomalidomide and how does it work? Pomalidomide is a third-generation immunomodulatory drug that belongs to the same class as thalidomide and lenalidomide. It works by modulating the immune system, directly attacking tumor cells, inhibiting angiogenesis (formation of new blood vessels), and affecting the bone marrow microenvironment. These mechanisms make it effective in treating multiple myeloma and potentially other conditions.
  • What conditions is pomalidomide being studied for in clinical trials? Pomalidomide is primarily being studied for multiple myeloma, especially in relapsed or refractory cases. However, clinical trials are also exploring its use in other conditions such as soft tissue sarcomas, Waldenstrom macroglobulinemia, and hereditary hemorrhagic telangiectasia.
  • What are the common side effects of pomalidomide? Common side effects of pomalidomide include bone marrow suppression (leading to low blood counts), skin reactions, gastrointestinal issues, and increased risk of infections. Peripheral neuropathy is less common than with thalidomide, and the risk of blood clots is generally low (less than 5%).
  • How is pomalidomide administered in clinical trials? Pomalidomide is typically administered orally, with dosing schedules varying between trials. Common regimens include daily dosing for 21 days out of a 28-day cycle, or continuous daily dosing. Doses may range from 2 mg to 4 mg per day, depending on the specific trial and patient tolerability.
  • What are some promising results from pomalidomide clinical trials? Clinical trials have shown pomalidomide to be effective in treating relapsed or refractory multiple myeloma, with some studies reporting objective response rates of over 60%. It has also demonstrated potential in maintenance therapy after stem cell transplantation and in combination with other drugs. Additionally, early studies suggest it may be beneficial in treating other conditions like soft tissue sarcomas and hereditary hemorrhagic telangiectasia.

Ongoing Clinical Trials on Pomalidomide

  • Study of Belantamab Mafodotin Alone and with Drug Combination for Patients with Relapsed/Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    France Norway Poland Sweden

  • Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +7

  • Study on the Effectiveness of Isatuximab, Pomalidomide, and Dexamethasone for Patients with AL Amyloidosis Not Responding Well to Previous Treatments

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +4

  • Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +8

  • Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +4

  • Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. It leads to the overproduction of abnormal plasma cells, causing various complications.
  • Immunomodulatory Drug: A type of medication that modifies or influences the immune system's function. In cancer treatment, these drugs can enhance the body's ability to fight cancer cells.
  • Relapsed Multiple Myeloma: A condition where multiple myeloma returns after a period of remission or improvement following treatment.
  • Refractory Multiple Myeloma: A form of multiple myeloma that does not respond to standard treatments or progresses within 60 days of the last therapy.
  • Autologous Hematopoietic Stem Cell Transplantation (ASCT): A procedure where a patient's own stem cells are collected, stored, and then reinfused after high-dose chemotherapy to help restore blood cell production.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Complete Remission (CR): The disappearance of all signs of cancer in response to treatment.
  • Minimal Residual Disease (MRD): The small number of cancer cells that remain in the body during or after treatment, often undetectable by standard tests.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • Waldenstrom Macroglobulinemia: A rare type of blood cancer characterized by an excess of abnormal white blood cells in the bone marrow.
  • Hereditary Hemorrhagic Telangiectasia: A genetic disorder that causes abnormal blood vessel formation leading to bleeding in various parts of the body.
  • Soft Tissue Sarcoma: A type of cancer that begins in the soft tissues of the body, including muscle, fat, blood vessels, nerves, and deep skin tissues.

References

  1. https://clinicaltrials.gov/study/NCT01745640
  2. https://clinicaltrials.gov/study/NCT02164955
  3. https://clinicaltrials.gov/study/NCT01053949
  4. https://clinicaltrials.gov/study/NCT00717522
  5. https://clinicaltrials.gov/study/NCT03288974
  6. https://clinicaltrials.gov/study/NCT03257631
  7. https://clinicaltrials.eu/trial/study-on-elranatamab-and-daratumumab-for-patients-with-relapsed-or-refractory-multiple-myeloma-after-prior-treatment/